Chimerix to Present at Cowen and Company 42nd Annual Health Care Conference

DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer and Mike Andriole, Chief Financial and Business Officer, will participate in a fireside chat at the Cowen and Company 42nd Annual Health Care Conference on Monday, March 7, 2022 at 12:50 p.m. ET.

An audio webcast of the fireside chat will be available on the Investor Relations section of Chimerix’s website at

ir.chimerix.com

, where it will be archived for approximately 90 days.


About Chimerix

Chimerix is a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA® for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M-mutant glioma as its lead indication. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.


CONTACT:

Investor Relations:

Michelle LaSpaluto

919 972-7115


[email protected]

Will O’Connor

Stern Investor Relations

212-362-1200


[email protected]


Primary Logo